Case study: Returning to us

Some of the researchers we feature are keen to experience what it is like to publish an article in a magazine that is not a scholarly publication. Some want the chance to see how communicators translate their publications and data in different ways. Some are keen to showcase a completed project, while others want to explain a research plan or ongoing study. Some must abide by funder requirements, while others plan to engage patients in their own treatment. Some seek a summary of research findings that is less technical than a preprint.

Other researchers, such as Dr Roustem Miftahof, have a clear goal in mind. Here, we look into the metrics of the two articles we published based on his works in 2025, and present his testimonial of the experience.

In February 2025, we discovered that AI digital twins are a reality. To identify novel therapeutic targets for the diagnosis and management of functional dyspepsia, Dr Alexander Hermann and Dr Miftahof have been tackling innovative ways to understand disease. Bridging medicine, biology, computer science, and mathematics, researchers that work at the interface of research disciplines are able to access innovations like no others.

The article explaining this research (https://doi.org/10.33548/SCIENTIA1206) proved a hit, reaching well over 50,000 viewers across social networks. The majority of readers were aged below 30, which validates this type of content targeted for the dissemination of complex information to digital savvy audiences.

In June 2025, the team was joined by Prof Dr Volker Hesselmann to address the limitations of traditional neuroradiology imaging techniques and validate a digital analogue of the brain. We learned that the development of another computational platform was underway, this one geared at personalised rehabilitation efforts to enable the treatment of stroke.

The resulting article (https://doi.org/10.33548/SCIENTIA1274) performed even better than the previous one. Knowledge of the production and marketing processes may have been responsible in part, but the new design certainly helped. The reach of this research was broad, and well balanced between genders across their preferred socials. Notably, the readership hailed from 4 continents: Europe, Asia, North America, and South America.

At ABS Technologies LLC, we have primarily used the articles published in Scientia for the promotion and dissemination of our research activities. These publications have proven to be highly effective in increasing the visibility of our work. For example, our most recent article attracted nearly 80,000 readers across the Scientia website and associated platforms, such as X and Facebook. This level of engagement is remarkable and demonstrates the magazine’s strength as a communication engine for reaching a broad audience.

It is important to emphasize that Scientia is not a scientific journal intended for publishing disputed or unverified findings. Rather, its scope is clear: the dissemination of knowledge and the provision of accessible updates on scientific progress for a wide readership. Suggestions that it is a predatory journal are therefore unfounded, as they stem from a misunderstanding of its mission as a promoter of science and innovation.

We greatly appreciate the work carried out by Scientia and would strongly recommend it to colleagues in both business and academia, as an excellent platform for increasing research visibility and fostering public engagement. We are very pleased with the outcomes and look forward to continuing our collaboration with Scientia.

Dr R. Miftahof, MD, PhD, DSc

CEO, ABS Technologies LLC

SHARE

DOWNLOAD E-BOOK

REFERENCE

https://doi.org/10.33548/Issue154.03

REPUBLISH OUR ARTICLES

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence (CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

SUBSCRIBE NOW


Follow Us

MORE ARTICLES YOU MAY LIKE

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Recurrent Aphthous Stomatitis (RAS) is an oral condition characterized by one or several painful mucosal ulcers. RAS affects a large proportion of the population and has a point prevalence of approximately 2–3%, daily. The etiology remains unknown, and there is currently no curative treatment. Most patients experience recurring episodes over time, with each episode typically lasting up to a week. Here, we describe the development of a mucoadhesive patch which, when applied over a RAS ulcer, provides rapid pain relief. The patch is easy for patients to apply when symptoms begin and has the potential to be used as an over-the-counter product. The development of the Mucocort mucoadhesive patch is an example of a Close-to-Market innovation strategy that embraces simplicity within a complex healthcare system. By simplifying the product concept, the team has reduced the number of regulatory steps required before market approval. This MedTech/Pharma innovation model, known as the “4R” framework – Re-purposing, Re-formulation, Re-positioning, and Re-patenting – has guided the program from concept to commercialization. In addition to the biodegradable mucoadhesive patch developed for RAS ulcers, the team is extending the innovation concept to a mucoadhesive gel formulation for the prevention and treatment of chemotherapy-induced mucositis. This gel-based program is being commercialized separately through MucoShield.

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease headon. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

For many parents, a child’s snoring may seem harmless, even endearing. Yet in some cases, it signals something more serious. Obstructive sleep apnoea is a condition in which a child’s breathing is repeatedly disrupted during sleep. These interruptions can affect growth, behaviour, and learning. Children with this condition may toss and turn at night, struggle to concentrate during the day, or show signs of hyperactivity and fatigue. Traditionally, enlarged tonsils and adenoids have been seen as the main culprits. Surgery to remove them has long been considered the standard treatment. However, research led by Consultant ENT Surgeon Ms. Aikaterini Dritsoula of The Leeds Teaching Hospitals NHS Trust invites us to look deeper. Her work suggests that the story is often more complex, especially in very young children.